Clinical Trial Update: Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ipilimumab alone versus ipilimumab plus nivolumab in melanoma patients who progressed on PD-1 inhibitors; results completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Parker Institute for Cancer Immunotherapy | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21